Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296644 | 1.00 | GRIN1 (0.37) | GRIN1GRIN2BKCNH2MCHR2MCHR1 | |
| SCHEMBL4302632 | 0.90 | DPP4 (0.34) | GRIN1GRIN2BDPP4CYP19A1 | |
| SCHEMBL4294737 | 0.90 | DPP4 (0.34) | GRIN1GRIN2BDPP4CYP19A1 | |
| SCHEMBL27759442 | 0.86 | GRIN1 (0.40) | GRIN1GRIN2BKCNH2DPP4CYP19A1 | |
| SCHEMBL4298230 | 0.85 | KCNH2 (0.38) | GRIN1GRIN2BKCNH2MCHR2MCHR1 | |
| SCHEMBL4296917 | 0.85 | KCNH2 (0.38) | GRIN1GRIN2BKCNH2MCHR2MCHR1 | |
| SCHEMBL3861905 | 0.84 | BPTF (0.41) | GRIN1GRIN2BKCNH2MCHR2MCHR1 | |
| SCHEMBL3862111 | 0.84 | KCNH2 (0.44) | GRIN1GRIN2BKCNH2 | |
| SCHEMBL4294672 | 0.81 | HTR7 (0.38) | KCNH2DPP4 | |
| SCHEMBL706822 | 0.79 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | GRIN1 3460/4885GRIN2B 3307/4885KCNH2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.